{"filing":{"accession_number":"0001171843-26-006678","cik":"0001828253","ticker":"EVAX","company_name":"Evaxion A/S","form":"6-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"f6k_101926.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828253/000117184326006678/f6k_101926.htm"},"events":[{"id":35906,"run_id":33094,"accession_number":"0001171843-26-006678","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces three-year clinical trial data for EVX-01, Evaxion's lead personalized cancer vaccine candidate in advanced melanoma. The disclosure reports sustained clinical responses with no tumor progression at three-year follow-up, building on prior two-year data showing 75% objective response rate. While this is a clinical milestone for a development-stage biotech company, it does not fit the discrete event categories (no earnings release, M\u0026A, executive change, or restatement). The data announcement is material to investors assessing the company's pipeline progress and partnership potential, as noted in the CSO's statement regarding \"potential partnership discussions.\"","company_name":"Evaxion A/S","ticker":"EVAX","filing_date":"2026-10-19","form":"6-K","submitted_at":null,"items":[{"id":40135,"accession_number":"0001171843-26-006678","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces three-year clinical trial data for EVX-01, Evaxion's lead personalized cancer vaccine candidate in advanced melanoma. The disclosure reports sustained clinical responses with no tumor progression at three-year follow-up, building on prior two-year data showing 75% objective response rate. While this is a clinical milestone for a development-stage biotech company, it does not fit the discrete event categories (no earnings release, M\u0026A, executive change, or restatement). The data announcement is material to investors assessing the company's pipeline progress and partnership potential, as noted in the CSO's statement regarding \"potential partnership discussions.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T10:03:45.466618+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40135,"accession_number":"0001171843-26-006678","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces three-year clinical trial data for EVX-01, Evaxion's lead personalized cancer vaccine candidate in advanced melanoma. The disclosure reports sustained clinical responses with no tumor progression at three-year follow-up, building on prior two-year data showing 75% objective response rate. While this is a clinical milestone for a development-stage biotech company, it does not fit the discrete event categories (no earnings release, M\u0026A, executive change, or restatement). The data announcement is material to investors assessing the company's pipeline progress and partnership potential, as noted in the CSO's statement regarding \"potential partnership discussions.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T10:03:45.466618+00:00","company_name":"Evaxion A/S","ticker":"EVAX","filing_date":"2026-10-19"}]}